

Leo F Buckley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7932802/publications.pdf>

Version: 2024-02-01

66
papers

2,229
citations

293460

24
h-index

263392

45
g-index

66
all docs

66
docs citations

66
times ranked

3063
citing authors

#	ARTICLE	IF	CITATIONS
1	Correspondence on “Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study”™ by Potere et al. Annals of the Rheumatic Diseases, 2022, 81, e194-e194.	0.5	1
2	Targeting the NLRP3 inflammasome in cardiovascular diseases. , 2022, 236, 108053.		71
3	Prescribing Patterns of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD: A Cross-Sectional Registry Analysis. Kidney360, 2022, 3, 455-464.	0.9	22
4	Contemporary Trends in the Use of and Expenditures on Digoxin in the United States. American Journal of Cardiovascular Drugs, 2022, 22, 567-575.	1.0	3
5	Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension. Journal of the American College of Cardiology, 2021, 77, 1290-1299.	1.2	65
6	Virtual optimization of guideline-directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT-HF pilot study. European Journal of Heart Failure, 2021, 23, 1191-1201.	2.9	45
7	A phase 1 clinical trial of SP16, a first-in-class anti-inflammatory LRP1 agonist, in healthy volunteers. PLoS ONE, 2021, 16, e0247357.	1.1	7
8	Mid- to Late-Life Inflammation and Risk of Cardiac Dysfunction, HFpEF and HFrEF in Late Life. Journal of Cardiac Failure, 2021, 27, 1382-1392.	0.7	3
9	Stability of Alteplase for Catheter-Directed, Ultrasound-Facilitated Thrombolysis. Blood Advances, 2021, 5, 5283-5289.	2.5	1
10	Effect of a Physician/Pharmacist Collaborative Care Model on Time in Target Range for Systolic Blood Pressure: Post Hoc Analysis of the CAPTION Trial. Hypertension, 2021, 78, 966-972.	1.3	8
11	Cardiac Myosin Activation for the Treatment of Systolic Heart Failure. Journal of Cardiovascular Pharmacology, 2021, 77, 4-10.	0.8	5
12	Determinants of Cardiorespiratory Fitness in Patients with Heart Failure Across a Wide Range of Ejection Fractions. American Journal of Cardiology, 2020, 125, 76-81.	0.7	10
13	Ambulatory Treatment of Worsening Heart Failure With Intravenous Loop Diuretics: A Four-Year Experience. Journal of Cardiac Failure, 2020, 26, 798-799.	0.7	13
14	An opinion paper of the Cardiology Practice and Research Network of the American College of Clinical Pharmacy: Recommendations for training of cardiovascular pharmacy specialists in postgraduate year 2 residency programs. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 95-108.	0.5	1
15	Unintended Impact of US Food and Drug Administration Recalls on the Use of Contaminated and Non-Contaminated Angiotensin Receptor Blockers Among Medicaid Beneficiaries. Annals of Pharmacotherapy, 2020, 54, 615-616.	0.9	1
16	Acute Effects of Interleukin-1 Blockade Using Anakinra in Patients With Acute Pericarditis. Journal of Cardiovascular Pharmacology, 2020, 76, 50-52.	0.8	20
17	Medicaid Expansion and Utilization of Antihyperglycemic Therapies. Diabetes Care, 2020, 43, 2684-2690.	4.3	13
18	Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019. , 2020, 2, e0178.		34

#	ARTICLE	IF	CITATIONS
19	Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 75, 526-529.	0.8	18
20	Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2020, 9, e014941.	1.6	150
21	Correlation of laboratory haemoconcentration measures with filling pressures obtained via pulmonary arterial pressure sensors in ambulatory heart failure patients. <i>European Journal of Heart Failure</i> , 2020, 22, 1907-1911.	2.9	6
22	Changes in nationwide Medicare and Medicaid expenditures on lipid-lowering therapies after proprotein convertase/subtilisin type 9 inhibitor availability. <i>Journal of Clinical Lipidology</i> , 2020, 14, 315-321.e4.	0.6	1
23	Use of P2Y12 inhibitors among Medicaid beneficiaries between 2008 and 2018. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 539-541.	1.0	0
24	Use of Direct Oral Anticoagulants Among Patients With Limited Income and Resources. <i>Journal of the American College of Cardiology</i> , 2019, 73, 526-528.	1.2	11
25	Potential role for interleukin-1 in the cardio-renal syndrome. <i>European Journal of Heart Failure</i> , 2019, 21, 385-386.	2.9	9
26	Metabolic modulation predicts heart failure tests performance. <i>PLoS ONE</i> , 2019, 14, e0218153.	1.1	20
27	Omega-3 Red Blood Cell Content Is Associated with Fat Mass Index and Leptin in Subjects with Obesity and Heart Failure with Preserved Ejection Fraction (P21-001-19). <i>Current Developments in Nutrition</i> , 2019, 3, nzz041.P21-001-19.	0.1	0
28	Cardiovascular Safety of Gabapentinoids. <i>Current Emergency and Hospital Medicine Reports</i> , 2019, 7, 48-52.	0.6	2
29	Inhibiting NLRP3 Inflammasome Activity in Acute Myocardial Infarction: A Review of Pharmacologic Agents and Clinical Outcomes. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 74, 297-305.	0.8	23
30	Alirocumab in Acute Myocardial Infarction: Results From the Virginia Commonwealth University Alirocumab Response Trial (VCU-AlirocRT). <i>Journal of Cardiovascular Pharmacology</i> , 2019, 74, 266-269.	0.8	24
31	Noninvasive Hemodynamic Monitoring of Cocaine-Induced Changes in Cardiac Output and Systemic Vascular Resistance in Subjects With Chronic Cocaine Use Disorder. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 74, 528-534.	0.8	1
32	Novel and Emerging Therapeutics for Primary Prevention of Cardiovascular Disease. <i>American Journal of Medicine</i> , 2019, 132, 16-24.	0.6	5
33	Key Articles and Guidelines in the Management of Heart Failure: 2018 Update. <i>Journal of Pharmacy Practice</i> , 2019, 32, 77-92.	0.5	7
34	Recent advances in the treatment of chronic heart failure. <i>F1000Research</i> , 2019, 8, 2134.	0.8	7
35	Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2014-2018.	2.2	26
36	Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2018, 5, 372-378.	1.4	50

#	ARTICLE	IF	CITATIONS
37	Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: A subgroup analysis of high-risk ACCORDION trial participants. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1499-1502.	2.2	36
38	A Review of Thrombolysis in Venous Thromboembolism With an Analysis of Alteplase Admixture Stability. <i>Current Emergency and Hospital Medicine Reports</i> , 2018, 6, 54-61.	0.6	3
39	Interleukin-1 blockade in cardiovascular diseases: a clinical update. <i>European Heart Journal</i> , 2018, 39, 2063-2069.	1.0	135
40	Interleukin-1 Blockade in Cardiovascular Diseases: From Bench to Bedside. <i>BioDrugs</i> , 2018, 32, 111-118.	2.2	29
41	Interleukin-1 blockade for the treatment of pericarditis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 46-53.	1.4	49
42	Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1629-1647.	1.4	31
43	C-Reactive Protein and N-Terminal Pro-brain Natriuretic Peptide Levels Correlate With Impaired Cardiorespiratory Fitness in Patients With Heart Failure Across a Wide Range of Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 178.	1.1	21
44	IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018, 11, e005036.	1.6	129
45	Burden of nursing activities during hemodynamic monitoring of heart failure patients. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2018, 47, 304-307.	0.8	1
46	Primary and Secondary Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2018, 122, 1578-1587.	0.7	37
47	Effect of Interleukin-1 Blockade on Left Ventricular Systolic Performance and Work. <i>Journal of Cardiovascular Pharmacology</i> , 2018, 72, 68-70.	0.8	19
48	Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease. <i>Drugs in R and D</i> , 2017, 17, 65-72.	1.1	33
49	Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	131
50	Dietary Fat, Sugar Consumption, and Cardiorespiratory Fitness in Patients With Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2017, 2, 513-525.	1.9	51
51	Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. <i>Diabetes Care</i> , 2017, 40, 1733-1738.	4.3	98
52	Severely Impaired Cardiorespiratory Fitness in Patients With Recently Decompensated Systolic Heart Failure. <i>American Journal of Cardiology</i> , 2017, 120, 1854-1857.	0.7	10
53	Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	171
54	Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age. <i>Clinical Cardiology</i> , 2017, 40, 46-52.	0.7	25

#	ARTICLE	IF	CITATIONS
55	Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up. Drug Design, Development and Therapy, 2017, Volume 11, 2121-2129.	2.0	10
56	Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2). Clinical Cardiology, 2017, 40, 626-632.	0.7	56
57	Interleukin-1 Blockade in Acute Decompensated Heart Failure. Journal of Cardiovascular Pharmacology, 2016, 67, 544-551.	0.8	98
58	Aminocaproic acid for the management of bleeding in patients on extracorporeal membrane oxygenation: Four adult case reports and a review of the literature. Heart and Lung: Journal of Acute and Critical Care, 2016, 45, 232-236.	0.8	21
59	A Systematic Review of Beliefs About Hypertension and its Treatment Among African Americans. Current Hypertension Reports, 2016, 18, 52.	1.5	27
60	A review of PCSK9 inhibition and its effects beyond LDL receptors. Journal of Clinical Lipidology, 2016, 10, 1073-1080.	0.6	39
61	Comparison of Ambulatory, High-Dose, Intravenous Diuretic Therapy to Standard Hospitalization and Diuretic Therapy for Treatment of Acute Decompensated Heart Failure. American Journal of Cardiology, 2016, 118, 1350-1355.	0.7	14
62	Obesity Contributes to Exercise Intolerance in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2016, 68, 2487-2488.	1.2	56
63	Intravenous Diuretic Therapy for the Management of Heart Failure and Volume Overload in a Multidisciplinary Outpatient Unit. JACC: Heart Failure, 2016, 4, 1-8.	1.9	70
64	Regulatory, legislative, and policy updates with anticoagulant use. Journal of Thrombosis and Thrombolysis, 2015, 39, 273-287.	1.0	0
65	Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. Current Emergency and Hospital Medicine Reports, 2013, 1, 83-97.	0.6	133
66	Efficacy and safety of novel anticoagulants compared with established agents. Therapeutic Advances in Hematology, 2011, 2, 175-195.	1.1	13